BC Extra | Nov 18, 2019
Clinical News

Karuna quintuples in value as schizophrenia combo clears Phase II bar

Karuna added about $1.8 billion in market cap Monday after a Phase II trial showed its combo therapy targeting muscarinic receptors led to significantly lower psychosis scores in patients with schizophrenia while avoiding the side...
BC Extra | Apr 26, 2019
Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
BC Extra | Mar 18, 2019
Financial News

Karuna looks past schizophrenia with $68M series B

Karuna intends to execute on its broader ambitions for lead program KarXT xanomeline/trospium chloride beyond schizophrenia, including development in at least two new indications, after raising $68 million in series B funding. By late 2019,...
BioCentury | Aug 3, 2018
Finance

Karuna’s CNS double play

With $42 million in series A funding, Karuna Pharmaceuticals Inc. hopes its combination of muscarinic receptor-targeting therapies can lead to clinical benefits in CNS disorders without the peripheral side effects seen in previous studies. Along...
BC Week In Review | Aug 3, 2018
Financial News

Karuna raises $42M series A

Karuna Pharmaceuticals Inc. (Boston, Mass.) raised $42 million in a series A round from Arch Venture Partners, the Wellcome Trust, Steven Paul, PureTech Health plc (LSE:PRTC) and other undisclosed investors. Karuna's lead product is KarXT...
BC Extra | Aug 2, 2018
Financial News

Karuna raises $42M series A

Karuna Pharmaceuticals Inc. (Boston, Mass.) raised $42 million in a series A round from Arch Venture Partners, the Wellcome Trust, Steven Paul, PureTech Health plc (LSE:PRTC) and other undisclosed investors. Karuna's lead product is KarXT...
BC Week In Review | Apr 6, 2018
Company News

Dermavant acquires compound from TheraVida

The Dermavant Sciences dermatology subsidiary of Roivant Sciences GmbH (Basel, Switzerland) in-licensed from TheraVida Inc. (San Mateo, Calif.) rights to develop and commercialize hyperhidrosis candidate RVT-504 (formerly THVD-102). TheraVida will receive an upfront payment and...
BC Week In Review | Sep 26, 2016
Clinical News

Xanomeline plus trospium chloride: Phase I started

Karuna began a double-blind, placebo-controlled, U.S. Phase I trial to compare 75 mg oral xanomeline thrice daily plus 20 mg oral trospium chloride twice daily for 7 days vs. xanomeline alone in up to 70...
BC Innovations | Dec 4, 2014
Cover Story

GPCRs' grand plans

In a move to expand tenfold the number of known 3D structures of the highly druggable class of GPCRs, Amgen Inc. , Ono Pharmaceutical Co. Ltd. and Sanofi have teamed up with three academic organizations to...
BC Innovations | Feb 16, 2012
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Muscarinic acetylcholine receptor M2 (CHRM2; HM2) An in vitro study determined the structure of HM2, which could be used to...
Items per page:
1 - 10 of 17